Considering that PD-L1 inhibition is an established approach in clinical settings, our findings suggested that PD-L1 targeting therapy or a combination therapy targeting HIF-1α and IFN-γ might represent a promising novel strategy for treating HNSCC. The gene discussed is IFNG; the disease is head and neck squamous cell carcinoma.